Table 2 Patient demographics by treatment group
From: Multicenter clinical evaluation of a multi-dose formulation of propofol in the dog
Group | 1 | 2 | 3 | 4 | 5 | 6 | Total |
|---|---|---|---|---|---|---|---|
N | 23 | 25 | 25 | 22 | 22 | 21 | 138 |
Age (Years)1 | |||||||
Mean | 4.65 | 7.70 | 4.84 | 3.95 | 2.87 | 5.67 | 5.00 |
SD | 3.97 | 3.42 | 4.16 | 3.88 | 2.67 | 5.24 | 4.17 |
Range | (0.8-14.0) | (0.8-13.5) | (0.3-12.0) | (0.3-12.5) | (0.3-10.0) | (0.3-17.0) | (0.3-17.0) |
Weight (kg)1 | |||||||
Mean | 15.5 | 21.6 | 15.7 | 14.0 | 20.7 | 14.8 | 17.1 |
SD | 10.6 | 14.5 | 13.4 | 9.6 | 10.5 | 9.9 | 11.8 |
Range | (2–31) | (3–52) | (2–46) | (3–32) | (5–41) | (2–33) | (2–52) |
Gender (N [% Total])2 | |||||||
Male | 0 | 2 (8) | 8 (32) | 8 (36) | 13 (59) | 7 (33) | 38 (28) |
Male castrated | 9 (39) | 10 (40) | 10 (40) | 2 (9) | 2 (9) | 7 (33) | 40 (29) |
Female | 3 (13) | 0 | 1 (4) | 4 (18) | 5 (23) | 2 (10) | 15 (11) |
Female spayed | 11 (48) | 13 (52) | 6 (24) | 8 (36) | 2 (9) | 5 (24) | 45 (33) |
ASA status (N [% Total])2 | |||||||
I | 18 (78) | 16 (64) | 19 (76) | 16 (73) | 19 (86) | 13 (62) | 101 (73) |
II | 5 (22) | 9 (36) | 6 (24) | 6 (27) | 3 (14) | 8 (38) | 37 (27) |